CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Find out which cash back credit cards have no annual fee to suit your spending habits. Discover the perfect card for you today!
27,937 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
The Dow’s first-half drama centered on one tech mega-cap that stood out for all the wrong reasons. This article break...
Microsoft has faced a recent pullback, but the company’s cloud, AI, and productivity strengths create a path to meani...
Finding value in semiconductors is tough, but a disciplined approach can spot opportunities amid rapid tech change. L...
Alphabet ramps up AI-enabled cloud expansion and heavy spending, fueling the debate over whether it can become the ne...
The latest pullback in software-as-a-service stocks may feel painful, but it also creates patient-buying opportunitie...
February can test nerves, but smart stock selection pays off. Here are two robust candidates that align with the curr...
META sits at a pivotal moment. With AI-enabled engagement, ad momentum, and new monetization paths, analysts wonder i...
Nvidia’s slip headlines a cautious mood as GTC 2026 approaches. This deep dive explores what it means for tech stocks...
Rents have moved in a new direction, but not every landlord should raise them right away. This guide helps you decide...
Investors are keen on Ingevity (NGVT) 2026 earnings as the company reports Q1 results. This article breaks down the n...
Investors are scanning cannabis names for growth and resilience. Here are three clear reasons why Green Thumb Industr...